In recent years, the epizootic and epidemic situation of tuberculosis in animals and humans has worsened sharply in Ukraine. This is facilitated by the constant change in the morphology and biological properties of the causative agent of tuberculosis, the low efficiency of existing laboratory diagnostic methods (outdated bacteriology standards that do not meet European requirements), the emergence of multi-resistant strains of mycobacteria that are difficult to treat. Therefore, in recent decades, scientists of the world have been actively working on the creation of new chemotherapeutic agents with potential tuberculocidal and tuberculostatic activity.
 In recent decades, cases of isolation of multi-resistant strains of mycobacteria have been increasingly recorded, causing infection that is difficult to treat, which poses a significant threat to the health of animals and people. The World Health Organization constantly monitors the situation of epidemic and socially significant diseases in the world. Particular attention is paid to tuberculosis. In the last decade, the WHO has developed and successfully applied the so-called DOTS strategy in the world. The essence of DOTS (Directly Observed Treatment Short-course) is strictly controlled treatment with a short course of chemotherapy. Therefore, the search for new chemotherapeutic drugs for the treatment of tuberculosis infection is a priority area of pharmaceutical chemistry.
 One of the promising similar drugs are triazole derivatives, the active development of which continues at the department of natural sciences for foreign students and toxicological chemistry of the Zaporizhzhia State Medical University. Therefore, the direction of influence of these derivatives on epizootic strains of mycobacteria, the causative agents of animal tuberculosis, is promising.
Read full abstract